These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 30064414)

  • 41. Variability of MELD score during the year before liver transplantation.
    Oton-Nieto E; Barcena-Marugan R; Carrera-Alonso E; Blesa-Radigales C; Garcia-Gonzalez M; Nuño J; Plaza-Palacios G; Garcia-Plaza A
    Transplant Proc; 2005 Nov; 37(9):3887-8. PubMed ID: 16386573
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
    Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
    Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit.
    Lucey MR; Schaubel DE; Guidinger MK; Tome S; Merion RM
    Hepatology; 2009 Aug; 50(2):400-6. PubMed ID: 19472315
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum hypoalbuminemia predicts late mortality on the liver transplant waiting list.
    Porrett PM; Baranov E; ter Horst M
    Transplantation; 2015 Jan; 99(1):158-63. PubMed ID: 25050469
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disparities in Eurotransplant liver transplantation wait-list outcome between patients with and without model for end-stage liver disease exceptions.
    Umgelter A; Hapfelmeier A; Kopp W; van Rosmalen M; Rogiers X; Guba M;
    Liver Transpl; 2017 Oct; 23(10):1256-1265. PubMed ID: 28650098
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma.
    Samuel D; Colombo M; El-Serag H; Sobesky R; Heaton N
    Liver Transpl; 2011 Oct; 17 Suppl 2():S6-13. PubMed ID: 21858912
    [TBL] [Abstract][Full Text] [Related]  

  • 47. List and liver transplant survival according to waiting time in patients with hepatocellular carcinoma.
    Salvalaggio PR; Felga G; Axelrod DA; Della Guardia B; Almeida MD; Rezende MB
    Am J Transplant; 2015 Mar; 15(3):668-77. PubMed ID: 25650130
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatitis C Virus Positive Patients on the Waiting List for Liver Transplantation: Turnover and Characteristics of the Population on the Eve of the Therapeutic Revolution With Direct-Acting Antivirals.
    Trapani S; Rizzato L; Masiero L; Ricci A; Morabito V; Peritore D; Fiaschetti P; Del Sordo E; Cacciotti AR; Montemurro A; Nanni Costa A
    Transplant Proc; 2017 May; 49(4):658-666. PubMed ID: 28457366
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does the meld system provide equal access to liver transplantation for patients with different ABO blood groups?
    IJtsma AJ; van der Hilst CS; Nijkamp DM; Bottema JT; Fidler V; Porte RJ; Slooff MJ
    Transpl Int; 2016 Aug; 29(8):883-9. PubMed ID: 26987934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Survival benefit after liver transplantation: a single European center experience.
    Ravaioli M; Grazi GL; Dazzi A; Bertuzzo V; Ercolani G; Cescon M; Cucchetti A; Masetti M; Ramacciato G; Pinna AD
    Transplantation; 2009 Sep; 88(6):826-34. PubMed ID: 19920783
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes.
    Trotter JF; Osgood MJ
    JAMA; 2004 Apr; 291(15):1871-4. PubMed ID: 15100206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of changes of model for end-stage liver disease score during waiting time on post-liver transplant mortality.
    Al-Freah MA; Gane EJ; Livingstone V; McCall J; Munn S
    Hepatol Int; 2012 Apr; 6(2):491-7. PubMed ID: 21717197
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Indications and timing of liver transplantation].
    Ruf AE; Villamil FG
    Acta Gastroenterol Latinoam; 2008 Mar; 38(1):75-88. PubMed ID: 18533359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Model for End-Stage Liver Disease-Sodium Score: The Evolution in the Prioritization of Liver Transplantation.
    Machicao VI
    Clin Liver Dis; 2017 May; 21(2):275-287. PubMed ID: 28364813
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list.
    Fisher RA; Maluf D; Cotterell AH; Stravitz T; Wolfe L; Luketic V; Sterling R; Shiffman M; Posner M
    Clin Transplant; 2004 Oct; 18(5):502-12. PubMed ID: 15344951
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of MELD Allocation System on Waiting List and Early Post-Liver Transplant Mortality.
    Jurado-García J; Muñoz García-Borruel M; Rodríguez-Perálvarez ML; Ruíz-Cuesta P; Poyato-González A; Barrera-Baena P; Fraga-Rivas E; Costán-Rodero G; Briceño-Delgado J; Montero-Álvarez JL; de la Mata-García M
    PLoS One; 2016; 11(6):e0155822. PubMed ID: 27299728
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Value of the MELD score for the assessment of pre- and post-liver transplantation survival.
    Adler M; De Gendt E; Vereerstraeten P; Degré D; Bourgeois N; Boon N; Gelin M; Ickx B; Donckier V
    Transplant Proc; 2005; 37(6):2863-4. PubMed ID: 16182835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.
    Ioannou GN; Perkins JD; Carithers RL
    Gastroenterology; 2008 May; 134(5):1342-51. PubMed ID: 18471511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma.
    Wong SN; Reddy KR; Keeffe EB; Han SH; Gaglio PJ; Perrillo RP; Tran TT; Pruett TL; Lok AS
    Liver Transpl; 2007 Mar; 13(3):334-42. PubMed ID: 17154401
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is the model of end-stage liver disease (MELD) valid in Israel? A critical analysis of liver transplant waiting list mortality.
    Ben-Haim M; Carmiel M; Katz P; Shabtai E; Oren R; Nakache R
    Isr Med Assoc J; 2006 Sep; 8(9):605-9. PubMed ID: 17058408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.